Key Summary Points {#FPar1}
==================

**Why carry out this study?**Opioids are treatment options for patients with osteoarthritis pain, and although such use may be of potential benefit in managing osteoarthritis pain, there is a need for understanding functional outcomes in these patientsThere are few data from the real-world clinical setting on the association of opioid use with pain interference with activities and daily function among adults with osteoarthritisThis exploratory, retrospective analysis evaluated the longitudinal association of opioid use with pain interference with daily activities and functional limitations among adults with osteoarthritis in the USA**What was learned from the study?**Regardless of baseline functional status, persistent opioid use in adults with osteoarthritis pain may be associated with poorer functional outcomesThese results highlight the importance of evaluating functional outcomes when assessing the potential benefits and risks of opioid use in patients with osteoarthritis and pain, and suggest a need for alternative pain management strategies

Introduction {#Sec1}
============

Osteoarthritis (OA), the most common form of arthritis, is one of the leading causes of global disability \[[@CR1]\]. In the USA, OA affects approximately 31 million individuals, and the prevalence appears to be increasing \[[@CR2], [@CR3]\]. Pain is a primary symptom of OA that impairs function and limits daily activities \[[@CR4]\]. The presence of pain increases the burden of OA by resulting in greater interference with daily activities, including reductions in work productivity and increasing healthcare resource utilization and associated costs relative to those without pain \[[@CR5]\].

In the absence of disease-modifying therapies, the management of OA is symptomatically driven, with the reduction of pain and the maintenance of function being the primary goals of long-term treatment \[[@CR6], [@CR7]\]. Although nonpharmacologic therapies (weight reduction, exercise, physical therapy) are generally recommended as part of an initial disease management strategy, nonsteroidal anti-inflammatory drugs (NSAIDs) are considered a first-line pharmacologic therapy for use in the short-term management of OA in specific subsets of patients (i.e., those not at high risk for gastrointestinal or cardiovascular events) \[[@CR6]--[@CR8]\]. However, opioids have been reported to be prescribed in as many as 40% of patients with OA \[[@CR9]--[@CR12]\], although these drugs are generally recommended in patients with OA specifically for intense or refractory pain and for those who do not respond to first-line treatment or have contraindications to other analgesics \[[@CR6]--[@CR8]\]. Furthermore, guidelines for the use of opioids in the management of chronic noncancer pain recommend that regimens be individualized and also require that the prescribing physician provide an evaluation of the risks and benefits \[[@CR13]\].

Although opioids may be prescribed to provide symptomatic pain relief and subsequent improved function, there is limited evidence on the relationship of opioid use and daily function in patients with OA in the real-world setting. A previous cross-sectional study reported prescription opioid use in nearly one-third (30.3%) of individuals with OA and showed that opioid users had a higher disease burden compared with those without opioid use, even after adjusting for relevant demographic and clinical variables \[[@CR14]\]. Furthermore, a study on the association of opioids and pain interference with activities (PIA) among individuals with OA showed that regardless of the level of PIA, opioid use increased the likelihood of specific categories of healthcare resource utilization including hospitalizations and emergency room visits, and was associated with higher costs relative to those not using opioids \[[@CR15]\]. The purpose of the current study is to explore longitudinal assessment of the association of opioid use with PIA and functional limitations among adults with OA in the USA.

Methods {#Sec2}
=======

Data Source and Study Sample {#Sec3}
----------------------------

The data source for this exploratory, retrospective, longitudinal study was the Medical Expenditure Panel Survey (MEPS) for 2010--2015. MEPS is sponsored by the Agency for Healthcare Research and Quality and is a nationally representative annual survey of the civilian noninstitutionalized population in the USA \[[@CR16], [@CR17]\]. Data collected from families and individuals during the survey included demographic characteristics; socioeconomic status; medical conditions; and health status, such as functional and activity limitations; as well as health-related quality of life; use of medical services; medical expenditures; access to care; and health insurance coverage. Because this study used secondary data from MEPS, which is a publicly available database, all ethics approvals and consent to participate were waived by the institutional review board at West Virginia University.

These data are collected in interview panels, with each panel following the same individuals for two consecutive years. A total of five rounds of data (interviews) are collected over the course of each 2-year panel (Fig. [1](#Fig1){ref-type="fig"}). This panel design enables longitudinal assessment of outcomes for each participant over a 2-year period. The current analysis was based on panels for 2010--2011, 2011--2012, 2012--2013, 2013--2014, and 2014--2015, corresponding to panels 15, 16, 17, 18, and 19, respectively, in the MEPS database.Fig. 1Study design and data collection. *MEPS* Medical Expenditure Panel Survey, *PIA* pain interference with daily activities

The criteria used for identification of the evaluated population was the same as that in a previously published study on the association of opioid use and PIA with economic outcomes \[[@CR15]\]. For inclusion in the analysis, adults (aged at least 18 years old) with OA were identified in the MEPS database for panels 15--19 from queries related to whether the respondent had "OA" in the full-year consolidated files or medical care encounters recorded in the medical condition files using the Clinical Classification Code (CCC) identifier 203. This CCC identifier matches to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 715.xx (osteoarthrosis and allied disorders). The CCC code of 203 also includes the ICD-9 code V134 (personal history of arthritis). This code was considered relevant because including this code could help identify patients with OA who did not seek healthcare services for OA in the year surveyed. Individuals reporting any cancer (CCC 11--44) were excluded.

Outcomes {#Sec4}
--------

The outcomes were PIA and functional limitations during the follow-up period (Fig. [1](#Fig1){ref-type="fig"}). PIA, which was collected in rounds 2 (baseline) and 4 (follow-up) in each panel, was derived from the 12-item Short Form Health Survey version 2 (SF-12 v2) health survey \[[@CR18]\]: "During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)?" with response options of "not at all," "a little bit," "moderately," "quite a bit," and "extremely." In the current analysis, these responses were recategorized as no/mild (responses of "not at all/a little bit"), moderate (response of "moderately"), and severe (responses of "quite a bit/extremely").

Changes in PIA groups were considered "better" if an individual moved from a higher to a lower PIA level during follow-up, "worse" if the movement was from a lower to a higher PIA level during follow-up, and "no change" if PIA levels were the same at both baseline and follow-up.

Functional limitations, dichotomized as "Yes" or "No" and collected in rounds 3 (baseline) and 5 (follow-up) in each panel, included any limitations in activities of daily living (ADL), instrumental ADL (IADL), physical activities, social function, work, and cognitive function. Although ADL is defined as the basic activities required for daily function (e.g., bathing, eating, dressing, transferring, toileting, and walking) \[[@CR19], [@CR20]\], IADL are not required for daily functioning but contribute to maintaining an individual's independence (e.g., housework, preparing meals, taking medications, shopping, telephoning, and managing money) \[[@CR21], [@CR22]\]. Changes in functional limitations were defined by the following four categories: "better" if an individual with a limitation at baseline was not limited at follow-up, "worse" if there was a limitation at follow-up in an individual with no limitation at baseline, "same" if there were limitations at baseline and follow-up, and those with no limitations at both baseline and follow-up.

Statistical Analysis {#Sec5}
--------------------

Study participants reported their opioid use at every round and thus definitions of opioid use patterns needed to account for the manner in which data were collected. Thus, persistent use was defined when opioid use was reported in at least two consecutive rounds before the last round of follow-up (rounds 1--3 for PIA analysis and rounds 2--4 for functional limitation analysis), and intermittent opioid use defined when reported in any one of the rounds; no opioid use was defined if such use was not reported in any of the rounds.

Unadjusted differences across the opioid use patterns for observed longitudinal changes in PIA and functional limitations were evaluated using Rao--Scott chi-square tests. Multinomial logistic regressions were conducted to examine the association between opioid use patterns and PIA during follow-up. Stratified multivariable logistic regressions explored the association of persistent or intermittent use of opioids versus no use of opioids with follow-up functional status; the stratification variable was the baseline functional status (i.e., patients with or without functional limitations at baseline).

Adjustment for covariates in the regression models was based on Andersen's Behavioral Model of Health Services Use that included demographics, comorbidities, and health characteristics \[[@CR23]\]. Specific variables included in this model were predisposing factors (age group, sex, race/ethnicity), enabling factors (marital status, educational level, employment status, economic status based on family income relative to the federal poverty line, health insurance coverage, prescription drug coverage), external environment (geographic region), need factors (number of comorbidities, depression and anxiety), and personal health practices (smoking status, body mass index, and physical activity \[at least five times a week\]). In the adjusted analyses, no opioid use with no/mild PIA was used as the reference group. The regression analyses also adjusted for the use of prescription NSAIDs, which was determined in every round and defined in a manner similar to that for opioid use (i.e., persistent, intermittent, and no use). Regression results are expressed as adjusted odds ratios (AOR) and their 95% confidence intervals (CIs).

All analyses account for the complex survey design of MEPS and were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC). Weights specifically assigned for longitudinal data files (LONGWT) were used to account for the longitudinal design. All reported results were weighted to be nationally representative.

Results {#Sec6}
=======

Population Characteristics {#Sec7}
--------------------------

A total of 4172 adults with OA were identified for inclusion in the analysis; the majority were female (66.2%), white (80.8%), and aged at least 50 years old (82.8%), with a high prevalence of overweight (32.4%) and obesity (40.4%; Table [1](#Tab1){ref-type="table"}). Approximately one-third of adults had opioid use in rounds 1--3 (35.4%) and 2--4 (32.7%), with intermittent use more prevalent than persistent use (Fig. [2](#Fig2){ref-type="fig"}). Prescription NSAID use was 25.3% in rounds 1--3 and 24.0% in rounds 2--4, with a slightly greater prevalence of intermittent use (Fig. [2](#Fig2){ref-type="fig"}).Table 1Characteristics in baseline year among adults with osteoarthritis, using pooled data from Medical Expenditure Panel Survey for the years 2010--2015 (*N* = 4172)VariableNumber (weighted %) of patientsFemale2858 (66.2)Race/ethnicity White2606 (80.8) African American754 (8.2) Latino540 (6.1) Other272 (4.8)Age distribution, years 18--39279 (6.3) 40--49496 (10.9) 50--641699 (41.0) 65--74946 (23.0) ≥ 75752 (18.8)Marital status Married2137 (56.3) Widow641 (14.3) Separated/divorced919 (20.2) Never married475 (9.2)Education Less than high school554 (9.4) High school951 (21.3) More than high school1777 (48.3) Missing890 (21.0)Employed1733 (44.7)Income Poor712 (12.3) Near poor938 (19.1) Middle income1153 (27.3) High income1369 (41.2)Health insurance coverage Private2382 (65.1) Public1467 (29.4) Uninsured323 (5.5)Prescription drug coverage1577 (42.8)Usual source of care3767 (90.9)Number of chronic conditions 0944 (23.7) 11052 (24.6) 2893 (21.4) ≥ 31283 (30.3)Depression/anxiety No depression or anxiety2959 (69.9) Depression only556 (13.3) Anxiety only390 (9.9) Depression and anxiety267 (6.8)Body mass index Under/normal weight993 (25.3) Overweight1329 (32.4) Obese1773 (40.4) Missing77 (1.9)Current smoker648 (14.5)Region Northeast740 (19.6) Midwest970 (24.6) South1592 (37.2) West870 (18.5)Fig. 2Patterns of use of opioids and prescription NSAIDs. *NSAID* nonsteroidal anti-inflammatory drug

Unadjusted Analysis {#Sec8}
-------------------

Changes from baseline to follow-up in PIA and functional status are presented in Table [2](#Tab2){ref-type="table"}, which also shows the unadjusted differences across the opioid use patterns. In the total population, 62.1% of patients had no PIA change, 17.9% worsened, and 20.0% improved. Although the majority of patients (51.0--93.1%) reported no limitations in each functional category, when changes did occur, patients more frequently reported that their functional status worsened (3.8--13.1%) than improved (1.1--11.3%). There was no statistically significant difference across opioid use patterns for changes in PIA, but the changes in all functional categories were statistically significant across the opioid use patterns (all *P* \< 0.001) (Table [2](#Tab2){ref-type="table"}). The proportion of adults who worsened was significantly higher among those with either persistent or intermittent opioid use compared with no opioid use, specifically for functional limitations in physical, social, and work activities.Table 2Changes in functional status and PIA from baseline to follow-upOutcomeNumber (%) of patients*P*^a^OverallNo opioid useIntermittent opioid usePersistent opioid usePIA (*n* = 4172)^b^ Same2544 (62.1)1718 (63.3)436 (58.2)390 (61.4) Better879 (20.0)553 (18.4)189 (24.4)137 (22.0) Worse749 (17.9)521 (18.3)121 (17.4)107 (16.6)NSFunctional limitations^c^ADL (*n* = 4102)\< 0.001 No limitation3771 (93.1)2501 (95.5)708 (92.0)562 (84.9) Same94 (1.9)42 (1.3)15 (2.1)37 (4.1) Better63 (1.1)21 (0.5)16 (1.8)26 (3.1) Worse174 (3.8)87 (2.7)33 (4.1)54 (8.0)IADL (*n* = 4101)\< 0.001 No limitation3509 (87.6)2368 (91.1)650 (85.9)491 (75.6) Same193 (4.1)102 (3.5)39 (4.7)52 (6.0) Better146 (2.8)61 (1.7)36 (3.8)49 (5.8) Worse253 (5.4)119 (3.7)47 (5.6)87 (12.5)Physical (*n* = 4098)\< 0.001 No limitation2055 (51.0)1583 (60.7)333 (42.5)139 (22.4) Same1037 (24.6)471 (17.5)226 (29.1)340 (48.0) Better484 (11.3)290 (10.4)98 (12.6)96 (13.5) Worse522 (13.1)303 (11.5)116 (15.7)103 (16.1)Social (*n* = 4094)\< 0.001 No limitation3166 (78.1)2239 (84.9)554 (72.4)373 (57.1) Same305 (7.0)118 (4.4)56 (6.5)131 (18.1) Better228 (5.1)103 (3.5)65 (7.2)60 (8.8) Worse395 (9.9)189 (7.1)94 (14.0)112 (15.9)Work (*n* = 4097)\< 0.001 No limitation2656 (67.1)1958 (75.5)445 (59.8)253 (41.7) Same731 (16.6)299 (10.9)163 (19.6)269 (36.5) Better271 (5.8)155 (5.2)70 (7.7)46 (6.4) Worse439 (10.4)239 (8.5)92 (12.9)108 (15.4)Cognitive (*n* = 4097)\< 0.001 No limitation3388 (85.1)2311 (89.5)633 (83.2)444 (69.5) Same266 (5.4)122 (4.0)42 (4.5)102 (12.3) Better185 (3.8)87 (2.8)45 (4.8)53 (6.5) Worse258 (5.7)126 (3.6)52 (7.4)80 (11.7)*ADL* activities of daily living, *IADL* instrumental activities of daily living, *NS* not significant, *PIA* pain interference with activities^a^Across the three opioid use patterns^b^From round 2 to round 4, with changes defined as "better" if PIA level was higher at follow-up relative to baseline; "worse" if PIA level was lower at follow-up than at baseline; and "no change" if PIA levels were the same at baseline and follow-up^c^From round 3 to round 5, with changes defined by 4 categories: "better" if an individual with a limitation at baseline was not limited at follow-up; "worse" if a limitation at follow-up was observed in an individual with no limitation at baseline; "same" if their limitations were present at baseline and follow-up; and those with no limitations at both baseline and follow-up

Adjusted Analyses {#Sec9}
-----------------

Multivariable regression analyses that adjusted for baseline sociodemographic and clinical characteristics, prescription NSAID use, and baseline PIA showed that relative to those without opioid use, persistent opioid users were approximately three times more likely to report extreme/severe PIA (AOR, 2.91; 95% CI, 1.95--4.32; *P* \< 0.001) and two times more likely to report moderate PIA (AOR, 2.04; 95% CI, 1.31--3.20; *P* \< 0.001) instead of mild/no PIA at follow-up (Fig. [3](#Fig3){ref-type="fig"}). No statistically significant differences were observed between intermittent and no opioid use for the changes in PIA at follow-up (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Adjusted OR for PIA at follow-up relative to no/mild PIA (referent) by opioid use pattern. ^a^Adjusted for baseline sociodemographic and clinical characteristics, prescription use of nonsteroidal anti-inflammatory drugs, and baseline PIA. *CI* confidence interval, *OR* odds ratio, *PIA* pain interference with activities

Patients who had functional limitations at baseline and persistent opioid use were statistically significantly more likely at follow-up to report work (AOR, 1.90; 95% CI, 1.06--3.39) and physical limitations (AOR, 1.63; 95% CI, 1.07--2.49) compared with those who had no opioid use (both *P* \< 0.05; Fig. [4](#Fig4){ref-type="fig"}a); no significant differences were observed for social or cognitive limitations. Among intermittent opioid users who had functional limitations at baseline, the odds of social and cognitive limitations at follow-up were significantly and substantially lower than among those with no opioid use; AOR, 0.35 (95% CI, 0.17--0.72) and AOR, 0.28 (95% CI, 0.13--0.62), respectively (both *P* \< 0.01). In this subpopulation of those with functional limitations at baseline, ADL and IADL could not be determined because of the small sample sizes, which resulted in a high relative standard error (\> 30%).Fig. 4Adjusted OR for functional limitations at follow-up by opioid use pattern among patients with osteoarthritis. ^a^Sample sizes were too small to evaluate ADL and IADL among patients with functional limitations at baseline. ^b^Adjusted for baseline sociodemographic and clinical characteristics, prescription use of nonsteroidal anti-inflammatory drugs, and baseline pain interference with daily activities. *ADL* activities of daily living, *CI* confidence interval, *IADL* instrumental activities of daily living, *OR* odds ratio

For patients without baseline functional limitations (Fig. [4](#Fig4){ref-type="fig"}b), persistent opioid users were significantly more likely to report cognitive, social, and physical limitations at follow-up, as well as limitations in performing IADL compared with those with no opioid use. The highest adjusted odds were for physical limitations (AOR, 2.39; 95% CI, 1.50--3.80; *P* \< 0.001), followed by cognitive limitations (AOR, 1.80; 95% CI, 1.13--2.84; *P* \< 0.05). Similarly, intermittent opioid users compared with those with no opioid use were more likely to report limitations in physical (AOR, 1.52; 95% CI, 1.02--2.26; *P* \< 0.05) and social (AOR, 1.44; 95% CI, 1.00--2.07; *P* \< 0.05) functions (Fig. [4](#Fig4){ref-type="fig"}b).

Discussion {#Sec10}
==========

OA is characterized by pain and functional impairment and, thus, it is important that therapeutic strategies effectively reduce pain and maintain daily function---outcomes that are the primary goals in the management of patients with OA \[[@CR6], [@CR7]\]. However, accumulating evidence has raised uncertainties about whether the small benefits of opioids in some patients outweigh their risks as a strategy for meeting these goals \[[@CR14], [@CR24], [@CR25]\]. This current study provides further evidence from real-world clinical settings that opioids, either with specific patterns of use or in certain subpopulations, may be associated with poorer outcomes with regard to maintaining function.

In particular, persistent opioid use appeared to be associated with greater negative effects than intermittent opioid use on PIA and function for a subset of patients. After adjusting for relevant demographic and clinical variables, we can interpret the statistically significant AORs of 2.91 and 2.04 for severe/extreme and moderate PIA, respectively, as approximate two- and threefold greater odds that patients with persistent use of opioids, relative to those without opioid use, report these levels of PIA instead of no PIA. Although there are limited data on the long-term use of opioids, these results are consistent with a recent study suggesting no additional benefits of long-term opioid use compared with other analgesic classes for pain-related function in a subset of patients with OA \[[@CR25]\]. Indeed, regardless of baseline functional status in the current study, persistent opioid use was associated with a high odds of limitations in functional categories, specifically physical limitations during follow-up, compared with those with no opioid use. There are many factors that could potentially contribute to these functional limitations, such as higher disease severity, obesity, and the ability of patients to cope with and adapt to limitations. It is also likely that some of these limitations may be attributed, at least in part, to the side effects of long-term opioid use, which can be exacerbated in an older population \[[@CR26]\] or in medically complex patients, such as those characterized by comorbid conditions and the use of polypharmacy \[[@CR27]\], both of which are common among patients with OA \[[@CR28]\]. Patients treated chronically with opioids may also become refractory to therapy, contributing to functional limitations. The generally greater association of PIA with physical limitations is considered as a proximal symptom of pain and is supported by previous studies in patients with OA, where increasing or unresolved pain was a predictor of functional decline, especially related to physical activities \[[@CR29]--[@CR31]\].

In contrast to persistent opioid use, intermittent opioid use appeared to be associated with a reduced likelihood of reporting social and cognitive limitations compared with no opioid use among those with such limitations at baseline; for those without baseline functional limitations, intermittent opioid use was still associated with a higher likelihood of patients reporting physical and social limitations. These results suggest that intermittent opioid use may be associated with reduced PIA and improved functional status in certain subgroups and, therefore, may be worth evaluating as a potential treatment strategy for managing OA pain in future studies in conjunction with individual patient and clinical characteristics. These findings must also be interpreted with caution because intermittent opioid users with baseline functional limitations may have likely adapted to their limitations and other unobserved factors, such as disease severity, pain self-efficacy, and use of complementary or alternative therapies, which may also have contributed to the results. Therefore, because this study was not designed to explore the reasons for the observed limitations associated with opioid use, additional studies are warranted to confirm these observations and characterize factors that may be associated with greater functional limitations among patients with OA who are using opioids.

A major strength of this study is that evaluated outcomes incorporated PIA and aspects of daily activities, such as social and cognitive function, which may be impacted differentially by pain and patterns of treatment. Although the outcomes measures used have not been specifically validated for such an analysis, this study was designed as an initial exploration of the associations between opioid use and daily function in patients with OA. Additional strengths include the fact that the analysis adjusted for a comprehensive set of variables that may be associated with the evaluated outcomes and that the study sample is nationally representative of the US population.

Despite adjustment for a range of variables, an important study limitation is that unobservable factors may exist that could account for some of the differences in outcomes, such as those previously noted with regard to disease severity, no or limited response with long-term use of opioids, length of opioid use prior to baseline, and the use of complementary/alternative therapies. Other limitations include the use of self-reported data, which may result in potential recall and social desirability bias. In addition, several limitations are specifically associated with the collection of the opioid data, including the fact that opioid use was self-reported and collected only at the round level, the actual opioids used were not identified, the sample size was not robust enough to further differentiate short-acting opioids from long-acting opioids, and there was insufficient information to calculate dosage and dosing frequency. The inability to incorporate information on strength and quantity of opioid medications while defining persistent and intermittent opioid use is another limitation, which resulted because there was a substantial amount of missing information (approximately 30%) for these variables in the MEPS database. The definition of long-term or persistent opioid use varies in the existing literature from 60 to 180 days or more \[[@CR32]--[@CR34]\]. Any two consecutive MEPS rounds are approximately 4--6 months apart; therefore, adults reporting opioid use in nonconsecutive rounds may have long-term use. The fact that PIA and functional limitations were not measured in the same rounds of the survey is another limitation, as is the lack of control for unobserved patient or disease characteristics that may potentially affect evaluated outcomes. In this regard, MEPS does not collect information on over-the-counter medications; the use of over-the-counter medications such as NSAIDs, as well as other treatment modalities, could impact an individual's pain level and functional ability. In addition, MEPS does not include institutionalized individuals or individuals living with undiagnosed OA, potentially reducing the generalizability of the results. Finally, analyses such as these are limited by the inability to link opioid prescriptions to the condition of interest. Thus, these findings must be interpreted as exploratory and associative rather than causal.

Conclusions {#Sec11}
===========

This real-world study suggests that persistent opioid use in adults with OA pain may be associated with poorer functional outcomes compared with OA pain without persistent opioid use. At follow-up, patients with persistent opioid use, especially those who did not have functional limitations at baseline, were more likely than patients without persistent opioid use to report limitations in daily function, especially related to physical activities. Persistent opioid use was also associated with a higher likelihood of moderate or severe/extreme PIA compared with no opioid use. Although opioids may be of benefit in some patients, these findings highlight the importance of evaluating the benefits and risks of opioids by the prescribing physician on an ongoing, case-by-case basis, taking into consideration patient characteristics and observed outcomes. Additionally, these findings suggest an unmet need for an alternative approach to pain management in a subgroup of patients with OA who use opioids. Future prospective studies are needed to validate these findings.
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